semaglutide hospitalizations SELECT Trial 12-month neurological and psychiatric outcomes
Description
While Ozempic is not FDA-approved for weight loss, many doctors are prescribing it for off-label usage
See how RYBELSUS performed in the PIONEER 3 Trial
Biomarkers and genetic predispositions can help personalize GLP-1 therapy
The proportion of participants experiencing gastrointestinal adverse events was similar between treatment groups (IcoSema 31.4%
Finally, we demonstrate that in mice, both the efficacy and tolerability of GLP1R agonists vary with the phase of the estrous cycle, being highest during proestrus (when estrogen levels peak) and lowest in diestrus (low estrogen levels)
